Stock Fundamentals

Company Information

▼
Company Name
Nkarta Inc
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
ISIN: US65487U1088
CIK: 0001787400
CUSIP: 65487U108
Currency: USD
Full Time Employees: 105
Phone: 925 407 1049
Website: https://www.nkartatx.com
Fiscal Year End: December
IPO Date: Jul 10, 2020
Description:

Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. The company's lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen, which is in Phase 1 clinical trial for the treatment of lupus nephritis; systemic sclerosis; idiopathic inflammatory myopathy; and antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis, as well as for systemic lupus erythematosus and myasthenia gravis. It has a research collaboration agreement with CRISPR Therapeutics AG. Nkarta, Inc. was incorporated in 2015 and is based in South San Francisco, California.

Address:

1150 Veterans Boulevard, South San Francisco, CA, United States, 94080

Directors & Officers

▼
Name Title Year Born
Mr. Paul J. Hastings CEO & Director 1960
Dr. Nadir Mahmood Ph.D. President and Principal Accounting & Financial Officer 1979
Dr. Shawn Rose M.D., Ph.D. Chief Medical Officer and Head of Research & Development NA

Institutional Holders

▼
Holder Name Shares Date Reported % Out Value % Change
RA Capital Management, LLC 10.81M Dec 31, 2025 15.21% $0.20 0.00%
TANG CAPITAL MANAGEMENT LLC 7.06M Sep 30, 2025 9.93% $0.56 0.00%
BlackRock Inc 3.70M Sep 30, 2025 5.21% $0.00 -10.96%
NEA Management Company, LLC 3.57M Dec 31, 2025 5.02% $0.34 0.00%
Samsara BioCapital, LLC 3.51M Dec 31, 2025 4.94% $0.67 -6.91%
SR ONE CAPITAL MANAGEMENT, LP 3.33M Dec 31, 2025 4.69% $0.87 0.00%
Citadel Advisors Llc 2.90M Sep 30, 2025 4.08% $0.00 -12.07%
Vanguard Group Inc 2.60M Dec 31, 2025 3.66% $0.00 4.24%
Alyeska Investment Group, L.P. 2.08M Dec 31, 2025 2.94% $0.01 0.01%
Monaco Asset Management 1.97M Sep 30, 2025 2.77% $0.25 24.48%
Renaissance Technologies Corp 1.70M Dec 31, 2025 2.40% $0.00 48.64%
Wasatch Advisors LP 1.58M Dec 31, 2025 2.22% $0.02 -3.75%
State Street Corp 1.15M Sep 30, 2025 1.62% $0.00 0.89%
JPMorgan Chase & Co 1.12M Sep 30, 2025 1.57% $0.00 93.37%
Geode Capital Management, LLC 1.07M Sep 30, 2025 1.50% $0.00 -11.61%
Two Sigma Investments LLC 971.98K Dec 31, 2025 1.37% $0.00 86.86%
Awm Investment Company Inc 906.00K Dec 31, 2025 1.28% $0.16 13.25%
Millennium Management LLC 748.49K Sep 30, 2025 1.05% $0.00 0.00%
Blackstone Inc 747.04K Sep 30, 2025 1.05% $0.01 0.00%
Peapod Lane Capital LLC 676.20K Dec 31, 2025 0.95% $1.06 0.73%

Shares Statistics

▼
Shares Outstanding: 71.03M
Shares Float: 56.31M
% Insiders: 497.40%
% Institutions: 7,841.80%
Short % Float: 10.92%

🏆 Top 10 Institutional Holders

▼
Rank Holder Name Shares Held % of Shares Change Date Reported
1 RA Capital Management, LLC 10.81M 15.21% ▲ 0.00% Dec 31, 2025
2 TANG CAPITAL MANAGEMENT LLC 7.06M 9.93% ▲ 0.00% Sep 30, 2025
3 BlackRock Inc 3.70M 5.21% ▼ 10.96% Sep 30, 2025
4 NEA Management Company, LLC 3.57M 5.02% ▲ 0.00% Dec 31, 2025
5 Samsara BioCapital, LLC 3.51M 4.94% ▼ 6.91% Dec 31, 2025
6 SR ONE CAPITAL MANAGEMENT, LP 3.33M 4.69% ▲ 0.00% Dec 31, 2025
7 Citadel Advisors Llc 2.90M 4.08% ▼ 12.07% Sep 30, 2025
8 Vanguard Group Inc 2.60M 3.66% ▲ 4.24% Dec 31, 2025
9 Alyeska Investment Group, L.P. 2.08M 2.94% ▲ 0.01% Dec 31, 2025
10 Monaco Asset Management 1.97M 2.77% ▲ 24.48% Sep 30, 2025

Valuation Metrics

▼
Enterprise Value: $-44.46M
Trailing P/E: 0.00
Forward P/E: 0.00

Financial Highlights

▼
Market Cap: $160.53M
EBITDA: $-106.94M
Book Value: $4.76
Earnings/Share: $-1.38
Profit Margin: 0.00%
Operating Margin: 0.00%
ROA (TTM): -15.14%
ROE (TTM): -26.69%
Revenue (TTM): $385.00
Revenue/Share (TTM): $0.00
Earnings Growth (YOY): 0.00%
Revenue Growth (YOY): 0.00%

Stock Price History

▼

1 Year Price History

2 Years Price History

5 Years Price History

10 Years Price History

Download Financials (Excel)

Financial Charts

▼

Revenue & Net Income (Yearly)

Revenue & Net Income (Quarterly)

Operating Expenses (Yearly)

Operating Expenses (Quarterly)

Balance Sheet (Yearly)

Balance Sheet (Quarterly)

Assets Breakdown (Yearly)

Assets Breakdown (Quarterly)

Liabilities Breakdown (Yearly)

Liabilities Breakdown (Quarterly)

Earnings Per Share (EPS) History

▼

Financial Ratios

▼

Earnings History

▼

Balance Sheet (Yearly)

▼

Financial Ratios

▼
Date Current Ratio Debt/Equity Debt/Assets Interest Coverage Debt/EBITDA
2024-12-31 14.45x 0.01x 0.19x N/A -0.05x
2023-12-31 10.85x 0.02x 0.28x N/A -0.05x
2022-12-31 16.36x 0.01x 0.21x -21.29x -0.04x
2021-12-31 18.99x 0.01x 0.08x -40.96x -0.03x
2020-12-31 36.10x 0.00x 0.05x -164.56x -0.03x
2019-12-31 4.56x -0.06x 1.53x -47.25x -0.08x
2018-12-31 3.96x 0.00x 1.56x N/A 0.00x

Insider Trading

Date Insider Name Title Transaction Type Shares Price Value
Jan 15, 2026 Nadir Mahmood N/A Sale 5.65K $2.07 $11.69K
Jan 15, 2026 Paul J Hastings N/A Sale 26.05K $2.07 $53.92K

📦 Raw API Data (JSON Explorer)

▼

Watchlist

0

No stocks in watchlist

Assistant

×
Hello! I'm your AI assistant. I have access to the financial data on this page. Ask me anything about NKTX.US!